Aprea Therapeutics, Inc. Logo

Aprea Therapeutics, Inc.

Developing precision cancer therapies targeting DNA Damage Response for solid tumors.

APRE | NDAQ

Overview

Corporate Details

ISIN(s):
US03836J1025
LEI:
Country:
United States of America
Address:
3805 OLD EASTON ROAD, 18902 DOYLESTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics through precision oncology. The company specializes in synthetic lethality-based therapies that target DNA Damage Response (DDR) pathways. Aprea's pipeline features small molecule drug candidates designed to maximize clinical efficacy while minimizing toxicity. The company is actively conducting clinical trials to evaluate its programs in patients with advanced solid tumors, aiming to provide new treatment options and improve outcomes for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aprea Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aprea Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aprea Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Develops & commercializes PET/CT tracers for diagnosing cancer & neurological disorders.
South Korea 176750
Dx & Vx Co., Ltd. Logo
Develops innovative diagnostics & vaccines and provides comprehensive life science contract services.
South Korea 180400
DYNAVAX TECHNOLOGIES CORP Logo
Biopharma firm developing novel vaccines, like its adult hepatitis B vaccine, with adjuvant tech.
United States of America DVAX
Dyne Therapeutics, Inc. Logo
Developing targeted therapies for genetic neuromuscular diseases via its FORCE™ platform.
United States of America DYN
Manufactures vet pharma for livestock/aquaculture & distributes premium pet food.
South Korea 044960
ECO ANIMAL HEALTH GROUP PLC Logo
Develops pharmaceuticals for respiratory & enteric diseases in global swine and poultry markets.
United Kingdom EAH
Ectin Research AB Logo
Clinical-stage biotech developing novel cancer treatments, focusing on metastatic bladder cancer.
Sweden ECTIN B
Edesa Biotech, Inc. Logo
Develops treatments for inflammatory and immune diseases like Acute Respiratory Distress Syndrome.
United States of America EDSA
Edgewise Therapeutics, Inc. Logo
Developing novel therapeutics for rare and serious muscle disorders.
United States of America EWTX
Editas Medicine, Inc. Logo
Developing CRISPR-based genomic medicines to treat serious and rare genetic diseases.
United States of America EDIT

Talk to a Data Expert

Have a question? We'll get back to you promptly.